RNA Targeting Small Molecule Drug Discovery Market - Global Strategic Business Report: Secure a US$5.3B Market by 2030 as Amgen, AstraZeneca, Roche and Merck Accelerate RNA Pipelines

What happened: ResearchAndMarkets.com added a global strategic business report on RNA targeting small molecule drug discovery, covering trends, competitive dynamics, and regional opportunities. Key numbers: Market valued at US$1.8 billion in 2024, projected to reach US$5.3 billion by 2030 at a 19.9% CAGR. Cancer segment forecast to reach US$2 billion by 2030 at 18.1% CAGR. Why it matters: The report cites AI-enabled discovery, RNA structural analysis, and pharma-biotech partnerships as growth drivers, with companies including Amgen, AstraZeneca, Roche, and Merck expanding RNA pipelines. Market: -0.9% today ($462.26), +43.1% YTD, 0.4x vol — as of 16:48 UTC Verified: Q3_2026 (Nov 3) revenue $9.7B vs $9.7B est; next print ~Feb 2

ResearchAndMarkets.com added a global strategic business report on RNA targeting small molecule drug discovery, covering trends, competitive dynamics, and regional opportunities.

The report cites AI-enabled discovery, RNA structural analysis, and pharma-biotech partnerships as growth drivers, with companies including Amgen, AstraZeneca, Roche, and Merck expanding RNA pipelines. Market: -0.9% today ($462.26), +43.1% YTD, 0.4x vol — as of 16:48 UTC Verified: Q3_2026 (Nov 3) revenue $9.7B vs $9.7B est; next print ~Feb 2